Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds
申请人:Neurogen Corporation
公开号:US07351826B2
公开(公告)日:2008-04-01
The invention provides compounds of Formula (I) that bind to GABAA receptors. In the above formula, variables are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies)
本发明提供了式(I)的化合物,其能够与GABAA受体结合。在上述式中,变量在此定义。这些化合物可以用于调节体内或体外GABAA受体的配体结合,并且在治疗人类、家养伴侣动物和家畜动物的各种中枢神经系统(CNS)疾病方面特别有用。所提供的化合物可以单独或与一个或多个其他CNS药剂联合使用,以增强其他CNS药剂的效果。还提供了用于治疗此类疾病的制药组合物和方法,以及用于检测GABAA受体的这些配体的方法(例如,受体定位研究)。